Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues

Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. The aim for insulin therapy is to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	diabetes mellitus glycemic control co-formulation of insulin analogs insulin degludec/insulin aspart ryzodeg hypoglycemia Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/e2877a380c0d452b888d1d55d75e3431
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e2877a380c0d452b888d1d55d75e3431
record_format	dspace
spelling	oai:doaj.org-article:e2877a380c0d452b888d1d55d75e34312021-11-14T09:00:19ZInsulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues2072-03512072-037810.14341/DM20144108-119https://doaj.org/article/e2877a380c0d452b888d1d55d75e34312014-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6851https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. The aim for insulin therapy is to mimic the physiological profile of insulin secretion seen in nondiabetic patients. Development of the insulin analogs has offered new opportunities in the diabetes management to achieve greater safety and tolerability of diabetes treatment. Insulin degludec/insulin aspart(IDegAsp) (Ryzodeg?, Novo Nordisk, Denmark) is the first soluble co-formulation of 70% ultra-long acting insulin degludec and 30% rapid-acting prandial insulin aspart, providing both basal insulin coverage and a prandial insulin bolus in a single injection. This review discusses data regarding the efficacy, safety, tolerability and clinical benefits of IDegAsp. According to the clinical development program IDegAspprovides an achievement of similar glycemic control with superiority in lowering FPG with using less number of injections and lower daily insulin dose, and also associated with numerically lower rates of confirmed and nocturnal confirmed hypoglycaemia in comparison with premixed or basal insulin analogues, as well as a basal component for basal?bolus therapy with supplementary mealtime insulin aspart.Trial results suggest that IDegAspQD or BID maybe an appropriate and reasonable option for initiating insulin therapy in type 1 and type 2 diabetic patients inadequately controlled on maximal doses of oral antidiabetic drugs,and also a simple alternative to basal?bolus treatment in patients who require intensification of insulin therapy, especially when adherence to more complex regimens is challenging.Ivan Ivanovich DedovMarina Vladimirovna ShestakovaEndocrinology Research Centrearticlediabetes mellitusglycemic controlco-formulation of insulin analogsinsulin degludec/insulin aspartryzodeghypoglycemiaNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 4, Pp 108-119 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus glycemic control co-formulation of insulin analogs insulin degludec/insulin aspart ryzodeg hypoglycemia Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus glycemic control co-formulation of insulin analogs insulin degludec/insulin aspart ryzodeg hypoglycemia Nutritional diseases. Deficiency diseases RC620-627 Ivan Ivanovich Dedov Marina Vladimirovna Shestakova Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
description	Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. The aim for insulin therapy is to mimic the physiological profile of insulin secretion seen in nondiabetic patients. Development of the insulin analogs has offered new opportunities in the diabetes management to achieve greater safety and tolerability of diabetes treatment. Insulin degludec/insulin aspart(IDegAsp) (Ryzodeg?, Novo Nordisk, Denmark) is the first soluble co-formulation of 70% ultra-long acting insulin degludec and 30% rapid-acting prandial insulin aspart, providing both basal insulin coverage and a prandial insulin bolus in a single injection. This review discusses data regarding the efficacy, safety, tolerability and clinical benefits of IDegAsp. According to the clinical development program IDegAspprovides an achievement of similar glycemic control with superiority in lowering FPG with using less number of injections and lower daily insulin dose, and also associated with numerically lower rates of confirmed and nocturnal confirmed hypoglycaemia in comparison with premixed or basal insulin analogues, as well as a basal component for basal?bolus therapy with supplementary mealtime insulin aspart.Trial results suggest that IDegAspQD or BID maybe an appropriate and reasonable option for initiating insulin therapy in type 1 and type 2 diabetic patients inadequately controlled on maximal doses of oral antidiabetic drugs,and also a simple alternative to basal?bolus treatment in patients who require intensification of insulin therapy, especially when adherence to more complex regimens is challenging.
format	article
author	Ivan Ivanovich Dedov Marina Vladimirovna Shestakova
author_facet	Ivan Ivanovich Dedov Marina Vladimirovna Shestakova
author_sort	Ivan Ivanovich Dedov
title	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
title_short	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
title_full	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
title_fullStr	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
title_full_unstemmed	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
title_sort	insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/e2877a380c0d452b888d1d55d75e3431
work_keys_str_mv	AT ivanivanovichdedov insulindegludecinsulinaspartisthefirstcoformulationofbasalandprandialinsulinanalogues AT marinavladimirovnashestakova insulindegludecinsulinaspartisthefirstcoformulationofbasalandprandialinsulinanalogues
_version_	1718429560558583808

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues

Ejemplares similares